Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACCP
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Access Pharmaceuticals
accesspharma.com/index.shtml

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

Full Access Pharmaceuticals profile here
Pdf

Access Pharmaceuticals inks deal to expand MuGard distribution

24th May 2011, 12:01 pm by Olivia D'Orazio
Access Pharmaceuticals inks deal to expand MuGard distribution

Access Pharmaceuticals (OTCBB:ACCP) announced Tuesday it has signed an agreement with eMax Health Systems to expand the distribution of the company's MuGard treatment.

Access, a biopharmaceutical company focused on supportive care products and treatments for use in the areas of oncology, diabetes and genetic diseases, will use eMax to further distribute its MuGard product, support its payer outreach programs, and advocate for reimbursement amoung U.S. commercial insurance carriers.

MuGard, which has already received FDA marketing clearance, is a ready-to-use oral wound rinse and coating, developed specifically for the treatment of oral mucositis, a common side effect of radiation and chemotherapy.

Approximately 40% of all patients undergoing chemotherapy and radiotherapy develop oral mucositis, and clinical guidelines for the prevention of oral mucositis recommend the use of a preventitive oral care regimen, like MuGard.

eMax, an independent research and pharmaceutical distribution support system, with its network of over 350 national, regional and local pharmacies, said it will provide support by maximizing patient access to Access' MuGard.

"The positive clinical feedback coupled with its favorable pharmacoeconomic value proposition makes MuGard a very important product to the oncology community," eMax CEO, Julian Casciano said.

"We look forward to providing additional support to ensure favorable MuGard formulary position among U.S. payers, hospitals, and large provider institutions."

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.